The ageing of the baby-boom generation, combined with new and emerging treatments for neurodegenerative disorders - including multiple sclerosis, Alzheimer's disease and Parkinson's disease - will lead to further expansion of the neurodegenerative therapies market. Increasing disease prevalence and a robust pipeline make that sector dynamic and highly promising for pharmaceutical and biotechnology companies worldwide. Our new report - World Neurodegenerative Diseases Market 2009-2024 - explains why, revealing where the most-exciting developments will lie from the present onwards.
This report examines markets for treating the following disorders in particular:
Parkinson's disease
Alzheimer's disease
Multiple sclerosis
Amyotrophic lateral sclerosis
Neuropathies.
Also covered are the following neurodegenerative disorders:
Huntington’s disease
Prion diseases.
What types of therapeutic agent are likely to enter the market from 2009 onwards, and will they hold the potential to dominate this market area? Where will the best commercial opportunities lie from 2009 onwards? What are the most-crucial drivers and restraints in this market? This report will provide you with the information that you need to understand current trends and future directions in neurodegenerative disorder therapies. In particular, we discuss prospects for the following products in detail:
Sifrol
Stalevo
Requip
Aricept
Namenda
Exelon
Reminyl
Avonex
Copaxone
Rebif
Betaferon
Rilutek.
In our pipeline analyses we include emerging therapeutics such as stem cells, gene therapy and monoclonal antibodies, among other prominent developments.
Detailed analysis of the neurodegenerative disorders market sector
World Neurodegenerative Diseases Market 2009-2024 examines that sector critically, through a comprehensive review of information sources, both primary and secondary. This report provides detailed sales forecasts, market share analyses, discussions of pipeline developments and analyses of commercial drivers and restraints, including a SWOT analysis. There are 63 tables and figures included, as well as three full interviews with relevant authorities. The result is a comprehensive market- and industry-centred study, with detailed analyses and informed opinion to benefit your work.
Research interviews from our comprehensive survey
This report contains visiongain interviews with the following relevant experts:
1) Dr Johan Luthman, former Global Head of Exploratory Medicine (Neurology, Autoimmune & Inflammatory Diseases), Merck Serono
2) Dr Allan Tobin, Senior Scientific Advisor to the CHDI Foundation
3) Professor Peter Jenner, founder and Chief Science Officer, Proximagen Neurosciences, and Professor in Pharmacology, King's College, University of London.
Why you should buy World Neurodegenerative Diseases Market 2009-2024
In this report you will receive the following benefits in particular:
You will assess the current market for neurodegenerative disease therapeutics
You will review the overall neurodegenerative disease therapeutics market, including a global sales forecast for 2009 to 2024
You will receive sales forecasts for neurodegenerative disorder submarkets from 2009 to 2024, with detailed discussions
You will receive sales forecasts for leading products from 2009 to 2024, with detailed discussions of market potential and competition
You will receive sales forecasts for leading geographical markets from 2009 to 2024, with informed discussion
You will examine commercial drivers and restraints in depth
You will discover the most-exciting pipeline developments in the sector, with informed commentary
You will discover expert opinions from our original survey of the sector, with prominent contributions from industry and academia.
Please Note: Reports are sold based on the user licenses indicated. The Publisher delivers the report in Flash format via the publisher website, allowing viewing and printing capabilities only. Within one to two business days after placing the order, the Publisher will email the client with information on accessing their purchase. Prior to initiating fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.
(0 items)
